{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:59Z","timestamp":1790806859770,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03482-3","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:39:30Z","timestamp":1770032370000},"page":"1060-1081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1547-6689","authenticated-orcid":false,"given":"Marcio Bezerra","family":"Barcellos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-6182","authenticated-orcid":false,"given":"Ant\u00f4nio","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6973-2408","authenticated-orcid":false,"given":"Raphael","family":"Alevato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-0649","authenticated-orcid":false,"given":"Sully","family":"Turon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6694-6569","authenticated-orcid":false,"given":"Gustavo Yano","family":"Callado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-2348","authenticated-orcid":false,"given":"Solange","family":"Artimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7386","authenticated-orcid":false,"given":"Sue Yazaki","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-3374","authenticated-orcid":false,"given":"Jorge","family":"Rezende-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6145-2532","authenticated-orcid":false,"given":"Edward","family":"Araujo J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-4333","authenticated-orcid":false,"given":"Andreia Cristina","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-898X","authenticated-orcid":false,"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4854-0642","authenticated-orcid":false,"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-9390","authenticated-orcid":false,"given":"Roberta","family":"Granese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"18","key":"3482_CR1","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1200\/JCO-24-02326","volume":"43","author":"C Lok","year":"2025","unstructured":"Lok C, van Trommel N, Braicu EI, et al. Practical guidelines for the treatment of gestational trophoblastic disease: collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD), European Society of Gynaecologic Oncology (ESGO), Gynecologic Cancer InterGroup (GCIG), and International Society for the Study of Trophoblastic Diseases (ISSTD). J Clin Oncol. 2025;43(18):2119\u201328.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"3482_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ijgo.70275","volume":"171","author":"HYS Ngan","year":"2025","unstructured":"Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynaecol Obstet. 2025;171(Suppl 1):78\u201386.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"3482_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2020.04.704","volume":"158","author":"F Freitas","year":"2020","unstructured":"Freitas F, Braga A, Viggiano M, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: a retrospective national cohort study. Gynecol Oncol. 2020;158(2):452\u20139.","journal-title":"Gynecol Oncol"},{"key":"3482_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bpobgyn.2021.01.005","volume":"74","author":"A Braga","year":"2021","unstructured":"Braga A, Elias KM, Horowitz NS, Berkowitz RS. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistant or relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021;74:81\u201396.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"3482_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/14656566.2022.2150075","volume":"24","author":"A Braga","year":"2023","unstructured":"Braga A, Paiva G, Cattai CJ, Elias KM, Horowitz NS, Berkowitz RS. Current chemotherapeutic options for the treatment of gestational trophoblastic disease. Expert Opin Pharmacother. 2023;24(2):245\u201358.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"3482_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.hoc.2024.08.014","volume":"38","author":"A Braga","year":"2024","unstructured":"Braga A, Paiva G, Alevato R, et al. Treatment of high-risk gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2024;38(6):1245\u201358.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3482_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ygyno.2022.12.020","volume":"170","author":"N Jareemit","year":"2023","unstructured":"Jareemit N, Therasakvichya S, Freitas F, et al. EMACO for treatment of gestational trophoblastic neoplasia: a multinational multicenter study. Gynecol Oncol. 2023;170:114\u201322.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"3482_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s11864-022-00988-8","volume":"23","author":"L Salman","year":"2022","unstructured":"Salman L, Bouchard-Fortier G, Covens A. Immune checkpoint inhibitors for the treatment of gestational trophoblastic neoplasia: rationale, effectiveness, and future fertility. Curr Treat Options Oncol. 2022;23(7):1035\u201343.","journal-title":"Curr Treat Options Oncol"},{"key":"3482_CR9","doi-asserted-by":"publisher","first-page":"1544585","DOI":"10.3389\/fimmu.2025.1544585","volume":"16","author":"J Zeng","year":"2025","unstructured":"Zeng J, Zhang J, Wang J, Xu L, Wang C, Yin R. Immunotherapy in gestational trophoblastic neoplasia: advances and future directions. Front Immunol. 2025;16:1544585.","journal-title":"Front Immunol"},{"issue":"10110","key":"3482_CR10","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","volume":"390","author":"E Ghorani","year":"2017","unstructured":"Ghorani E, Kaur B, Fisher RA, et al. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. Lancet. 2017;390(10110):2343\u20135.","journal-title":"Lancet"},{"issue":"27","key":"3482_CR11","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1200\/JCO.20.00803","volume":"38","author":"B You","year":"2020","unstructured":"You B, Bolze PA, Lotz JP, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase\u00a0II trial. J Clin Oncol. 2020;38(27):3129\u201337.","journal-title":"J Clin Oncol"},{"key":"3482_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ygyno.2022.11.005","volume":"168","author":"B You","year":"2023","unstructured":"You B, Bolze PA, Lotz JP, et al. Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: cohort B of the TROPHIMMUN phase\u00a02 trial. Gynecol Oncol. 2023;168:62\u20137.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"3482_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","volume":"22","author":"H Cheng","year":"2021","unstructured":"Cheng H, Zong L, Kong Y, et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase\u00a02 trial. Lancet Oncol. 2021;22(11):1609\u201317.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3482_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112782","volume":"14","author":"G Mangili","year":"2022","unstructured":"Mangili G, Sabetta G, Cioffi R, et al. Current evidence on immunotherapy for gestational trophoblastic neoplasia (GTN). Cancers (Basel). 2022;14(11):2782.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3482_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000533972","volume":"89","author":"IO Baas","year":"2024","unstructured":"Baas IO, Westermann AM, You B, Bolze PA, Seckl M, Ghorani E. Immunotherapy for gestational trophoblastic neoplasia: a new paradigm. Gynecol Obstet Invest. 2024;89(3):230\u20138.","journal-title":"Gynecol Obstet Invest"},{"issue":"3","key":"3482_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ijgc-2022-003771","volume":"33","author":"L Hennah","year":"2023","unstructured":"Hennah L, Seckl M, Ghorani E. Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy. Int J Gynecol Cancer. 2023;33(3):414\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"3482_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11864-024-01235-y","volume":"25","author":"X Wang","year":"2024","unstructured":"Wang X, Wu J, Xie W. Evolution of treatment strategies for gestational trophoblastic neoplasia: chemotherapy, immunotherapy, and molecular targeted therapy. Curr Treat Options Oncol. 2024;25(8):1055\u201362.","journal-title":"Curr Treat Options Oncol"},{"key":"3482_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"4","key":"3482_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/AOG.0000000000005998","volume":"146","author":"A Braga","year":"2025","unstructured":"Braga A, Berkowitz R, Horowitz N. Etiology, natural history, and management of recent advances in molar pregnancy. Obstet Gynecol. 2025;146(4):451\u201365.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"3482_CR20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.hoc.2024.07.003","volume":"38","author":"U Joneborg","year":"2024","unstructured":"Joneborg U. Epidemiology of gestational trophoblastic disease. Hematol Oncol Clin North Am. 2024;38(6):1173\u201390.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5\u20136","key":"3482_CR21","first-page":"241","volume":"59","author":"A Braga","year":"2014","unstructured":"Braga A, Uberti EM, Fajardo MC, et al. Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12\u00a0years since International FIGO 2000 consensus. J Reprod Med. 2014;59(5\u20136):241\u20137.","journal-title":"J Reprod Med"},{"issue":"3","key":"3482_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ygyno.2021.10.003","volume":"163","author":"NS Horowitz","year":"2021","unstructured":"Horowitz NS, Eskander RN, Adelman MR, Burke W. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: a Society of Gynecologic Oncology evidence-based review and recommendation. Gynecol Oncol. 2021;163(3):605\u201313.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3482_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ajog.2021.10.004","volume":"226","author":"JM Madi","year":"2022","unstructured":"Madi JM, Paganella MP, Litvin IE, et al. Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis. Am J Obstet Gynecol. 2022;226(5):633-45.e8.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"3482_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AOG.0000000000001554","volume":"128","author":"RJ Osborne","year":"2016","unstructured":"Osborne RJ, Filiaci VL, Schink JC, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol. 2016;128(3):535\u201342.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"3482_CR25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(21)00262-X","volume":"22","author":"A Braga","year":"2021","unstructured":"Braga A, Paiva G, Ghorani E, et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(8):1188\u201398.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3482_CR26","doi-asserted-by":"publisher","first-page":"390.e1","DOI":"10.1016\/j.ajog.2015.09.083","volume":"214","author":"PA Bolze","year":"2016","unstructured":"Bolze PA, Riedl C, Massardier J, et al. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of \u226513. Am J Obstet Gynecol. 2016;214(3):390.e1-8.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"3482_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","volume":"31","author":"C Alifrangis","year":"2013","unstructured":"Alifrangis C, Agarwal R, Short D, et al. EMA\/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31(2):280\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3482_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1200\/JCO.2014.57.5332","volume":"33","author":"P Savage","year":"2015","unstructured":"Savage P, Cooke R, O\u2019Nions J, et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol. 2015;33(5):472\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3482_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/his.13882","volume":"75","author":"L Zong","year":"2019","unstructured":"Zong L, Zhang M, Wang W, Wan X, Yang J, Xiang Y. PD-L1, B7\u2013H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. Histopathology. 2019;75(3):421\u201330.","journal-title":"Histopathology"},{"key":"3482_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ygyno.2024.01.033","volume":"184","author":"L McNally","year":"2024","unstructured":"McNally L, Wu S, Hodges K, et al. Molecular profiling of gestational trophoblastic neoplasia: identifying therapeutic targets. Gynecol Oncol. 2024;184:111\u20136.","journal-title":"Gynecol Oncol"},{"key":"3482_CR31","doi-asserted-by":"publisher","first-page":"1610918","DOI":"10.3389\/pore.2023.1610918","volume":"29","author":"H Cheng","year":"2023","unstructured":"Cheng H, Zong L, Yu S, et al. Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia. Pathol Oncol Res. 2023;29:1610918.","journal-title":"Pathol Oncol Res"},{"key":"3482_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2025.100583","volume":"80","author":"M Barcellos","year":"2025","unstructured":"Barcellos M, Braga A, Rech MM, et al. Pembrolizumab in gestational trophoblastic neoplasia: systematic review and meta-analysis with sub-group analysis of potential prognostic factors. Clinics. 2025;80:100583.","journal-title":"Clinics"},{"issue":"3","key":"3482_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/IGC.0000000000000892","volume":"27","author":"PA Bolze","year":"2017","unstructured":"Bolze PA, Patrier S, Massardier J, et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer. 2017;27(3):554\u201361.","journal-title":"Int J Gynecol Cancer"},{"key":"3482_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.humpath.2018.10.001","volume":"84","author":"B Lu","year":"2019","unstructured":"Lu B, Teng X, Fu G, et al. Analysis of PD-L1 expression in trophoblastic tissues and tumors. Hum Pathol. 2019;84:202\u201312.","journal-title":"Hum Pathol"},{"issue":"7","key":"3482_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111651","volume":"41","author":"AR Moore","year":"2022","unstructured":"Moore AR, Vivanco Gonzalez N, Plummer KA, et al. Gestationally dependent immune organization at the maternal-fetal interface. Cell Rep. 2022;41(7):111651.","journal-title":"Cell Rep"},{"issue":"1","key":"3482_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00281-025-01051-y","volume":"47","author":"X Hu","year":"2025","unstructured":"Hu X, Lai S, Liao A. Immune checkpoint for pregnancy. Semin Immunopathol. 2025;47(1):26.","journal-title":"Semin Immunopathol"},{"issue":"2","key":"3482_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/PGP.0000000000000305","volume":"36","author":"E Veras","year":"2017","unstructured":"Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol. 2017;36(2):146\u201353.","journal-title":"Int J Gynecol Pathol"},{"issue":"Suppl 1","key":"3482_CR38","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/S0090-8258(21)00968-9","volume":"162","author":"K Dugan","year":"2021","unstructured":"Dugan K, Yu R, Xing D, et al. Hot or not: defining trophoblast PD-L1 expression and lymphohistiocytic density in gestational trophoblastic neoplasia. Gynecol Oncol. 2021;162(Suppl 1):S171\u20132.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"3482_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020401","volume":"14","author":"O De Tommasi","year":"2025","unstructured":"De Tommasi O, Marchetti M, Tripepi M, et al. PD-1 and PD-L1 expression in endometrial cancer: a systematic review of the literature. J Clin Med. 2025;14(2):401.","journal-title":"J Clin Med"},{"key":"3482_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596825","volume":"11","author":"J Rotman","year":"2020","unstructured":"Rotman J, van der Zee AGJ, de Vries EGE, Boomsma DI. PD-L1 and PD-L2 expression in cervical cancer. Front Immunol. 2020;11:596825.","journal-title":"Front Immunol"},{"issue":"1","key":"3482_CR41","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1186\/s12885-024-13058-z","volume":"24","author":"D Huang","year":"2024","unstructured":"Huang D, Li S, Bai Y, Wang Y. Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis. BMC Cancer. 2024;24(1):1298.","journal-title":"BMC Cancer"},{"key":"3482_CR42","doi-asserted-by":"publisher","first-page":"1507977","DOI":"10.3389\/fimmu.2024.1507977","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Shen J, Huang M, Li R. Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase\u00a03 clinical trials. Front Immunol. 2024;15:1507977.","journal-title":"Front Immunol"},{"issue":"27","key":"3482_CR43","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/JCO.2017.74.4052","volume":"35","author":"M Huang","year":"2017","unstructured":"Huang M, Pinto A, Castillo RP, Slomovitz BM. Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol. 2017;35(27):3172\u20134.","journal-title":"J Clin Oncol"},{"key":"3482_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2019.08.024","volume":"121","author":"MC Choi","year":"2019","unstructured":"Choi MC, Oh J, Lee C. Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia. Eur J Cancer. 2019;121:94\u20137.","journal-title":"Eur J Cancer"},{"key":"3482_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100625","volume":"34","author":"KH Clair","year":"2020","unstructured":"Clair KH, Gallegos N, Bristow RE. Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep. 2020;34:100625.","journal-title":"Gynecol Oncol Rep"},{"key":"3482_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100574","volume":"32","author":"JA Goldfarb","year":"2020","unstructured":"Goldfarb JA, Dinoi G, Mariani A, Langstraat CL. A case of multi-agent drug resistant choriocarcinoma treated with pembrolizumab. Gynecol Oncol Rep. 2020;32:100574.","journal-title":"Gynecol Oncol Rep"},{"issue":"6","key":"3482_CR47","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.3390\/curroncol28060446","volume":"28","author":"D Pisani","year":"2021","unstructured":"Pisani D, Calleja-Agius J, Di Fiore R, et al. Epithelioid trophoblastic tumour: a case with genetic linkage to a child born over seventeen years prior, successfully treated with surgery and pembrolizumab. Curr Oncol. 2021;28(6):5346\u201355.","journal-title":"Curr Oncol"},{"key":"3482_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100819","volume":"37","author":"SG Bell","year":"2021","unstructured":"Bell SG, Uppal S, Sakala MD, Sciallis AP, Rolston A. An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab. Gynecol Oncol Rep. 2021;37:100819.","journal-title":"Gynecol Oncol Rep"},{"key":"3482_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100782","volume":"36","author":"A Porter","year":"2021","unstructured":"Porter A, Barcelon JM, Budker RL, et al. Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulae. Gynecol Oncol Rep. 2021;36:100782.","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"3482_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/AOG.0000000000004434","volume":"138","author":"B Polnaszek","year":"2021","unstructured":"Polnaszek B, Mullen M, Bligard K, Raghuraman N, Massad LS. Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy. Obstet Gynecol. 2021;138(1):115\u20138.","journal-title":"Obstet Gynecol"},{"key":"3482_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100817","volume":"37","author":"V Paspalj","year":"2021","unstructured":"Paspalj V, Polterauer S, Poetsch N, Reinthaller A, Grimm C, Bartl T. Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: a case report. Gynecol Oncol Rep. 2021;37:100817.","journal-title":"Gynecol Oncol Rep"},{"key":"3482_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.100955","volume":"40","author":"AJ Wong","year":"2022","unstructured":"Wong AJ, Finch L, Pearson JM, Pinto A, Huang M. Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy. Gynecol Oncol Rep. 2022;40:100955.","journal-title":"Gynecol Oncol Rep"},{"key":"3482_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101259","volume":"49","author":"M Lehmann","year":"2023","unstructured":"Lehmann M, Hosa H, Bartl T, et al. Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: a case report. Gynecol Oncol Rep. 2023;49:101259.","journal-title":"Gynecol Oncol Rep"},{"issue":"5","key":"3482_CR54","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.tjog.2023.07.019","volume":"62","author":"K Niimi","year":"2023","unstructured":"Niimi K, Yamamoto E, Oda Y, et al. A case of complete remission of intractable gestational choriocarcinoma with subsequent chemotherapy after pembrolizumab. Taiwan J Obstet Gynecol. 2023;62(5):745\u20138.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"3482_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101281","volume":"49","author":"M Helbig","year":"2023","unstructured":"Helbig M, Steinmann M, Jaschinski S, et al. Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature. Gynecol Oncol Rep. 2023;49:101281.","journal-title":"Gynecol Oncol Rep"},{"key":"3482_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2023.100260","volume":"78","author":"A Braga","year":"2023","unstructured":"Braga A, Balthar E, Souza LCS, et al. Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia\u2014systematic review with a presentation of the first 4 Brazilian cases. Clinics. 2023;78:100260.","journal-title":"Clinics"},{"key":"3482_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101304","volume":"50","author":"A Ramirez-Espinoza","year":"2023","unstructured":"Ramirez-Espinoza A, Vela I, Server L, Roudriguez-Celdr\u00e1n JM, Chuli\u00e1 MT, Quereda F. Placental-site trophoblastic tumor with bone metastasis: a diagnostic and therapeutic challenge. Gynecol Oncol Rep. 2023;50:101304.","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"3482_CR58","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s13023-025-04014-6","volume":"20","author":"X Cheng","year":"2025","unstructured":"Cheng X, Wang D, Wang X, et al. Gestational trophoblastic neoplasia with pancreatic metastasis: clinical characteristics, treatment strategies, and outcomes. Orphanet J Rare Dis. 2025;20(1):482.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3482_CR59","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1159\/000543518","volume":"18","author":"M Meyers","year":"2025","unstructured":"Meyers M, Awada A, Najmaoui M, et al. Metastatic gestational trophoblastic neoplasia leading to acute respiratory failure and death: a case report\u2014about a particularly challenging management in the intensive care unit, and exploring the potential of pembrolizumab in treating frail, pretreated gestational trophoblastic neoplasia. Case Rep Oncol. 2025;18(1):386\u201397.","journal-title":"Case Rep Oncol"},{"key":"3482_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101168","volume":"46","author":"BJ Matthews","year":"2023","unstructured":"Matthews BJ, Froehlich A, Goicochea L, Levinson K. Postmenopausal mixed gestational trophoblastic neoplasia with complete response to immunotherapy\u2014a case report. Gynecol Oncol Rep. 2023;46:101168.","journal-title":"Gynecol Oncol Rep"},{"key":"3482_CR61","doi-asserted-by":"publisher","first-page":"1391408","DOI":"10.3389\/fonc.2024.1391408","volume":"14","author":"A Enuset","year":"2024","unstructured":"Enuset A, Duck L, Petre C, Machiels JP, Goffin F. Case report: multidrug resistant gestational trophoblastic neoplasia: focus on failure of immunotherapy and success of high-dose chemotherapy. Front Oncol. 2024;14:1391408.","journal-title":"Front Oncol"},{"issue":"11","key":"3482_CR62","doi-asserted-by":"publisher","first-page":"90","DOI":"10.47895\/amp.v58i11.8008","volume":"58","author":"EK Jacinto","year":"2024","unstructured":"Jacinto EK. Chemo-resistant gestational trophoblastic neoplasia and the use of immunotherapy: a case report and review of literature. Acta Med Philipp. 2024;58(11):90\u20138.","journal-title":"Acta Med Philipp"},{"key":"3482_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101530","volume":"56","author":"A Brawley","year":"2024","unstructured":"Brawley A, Moffitt C, Bruce SF, Farabaugh CS, Podczaski E, Sorosky J. Use of a PD-1 checkpoint inhibitor in a patient with ultra-high-risk gestational trophoblastic neoplasia and gastrointestinal metastases. Gynecol Oncol Rep. 2024;56:101530.","journal-title":"Gynecol Oncol Rep"},{"issue":"11","key":"3482_CR64","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.ccell.2024.10.005","volume":"42","author":"EC Harrold","year":"2024","unstructured":"Harrold EC, Ogle M, O\u2019Brien E, et al. Fertility outcomes post immune checkpoint inhibitor exposure. Cancer Cell. 2024;42(11):1808\u201310.","journal-title":"Cancer Cell"},{"issue":"1","key":"3482_CR65","volume":"5","author":"A Le-Nguyen","year":"2022","unstructured":"Le-Nguyen A, Rys RN, Petrogiannis-Haliotis T, Johnson NA. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin\u2019s lymphoma. Cancer Rep (Hoboken). 2022;5(1):e1432.","journal-title":"Cancer Rep (Hoboken)"},{"key":"3482_CR66","unstructured":"NHS England. Urgent Clinical Commissioning Policy Statement: Pembrolizumab for drug-resistant gestational trophoblastic neoplasia. Reference 170027P. NHS England; Jan 2017. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/12\/Pembrolizumab-for-drug-resistant-gestational-trophoblastic-neoplasia.pdf. Accessed Nov 2, 2025."},{"key":"3482_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101974","volume":"59","author":"X Wang","year":"2023","unstructured":"Wang X, Cang W, Liu X, et al. Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective study. EClinicalMedicine. 2023;59:101974.","journal-title":"EClinicalMedicine"},{"key":"3482_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101760","volume":"59","author":"R Emlein","year":"2025","unstructured":"Emlein R, Palisoul M, Einstein H, et al. First-line pembrolizumab used concurrently with multi-agent chemotherapy and inhaled tranexamic acid (TXA) for management of stage III mixed trophoblastic tumor complicated by pulmonary hemorrhage. Gynecol Oncol Rep. 2025;59:101760.","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"3482_CR69","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/21645515.2018.1551671","volume":"15","author":"JM Collins","year":"2019","unstructured":"Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother. 2019;15(4):891\u2013908.","journal-title":"Hum Vaccin Immunother"},{"issue":"36","key":"3482_CR70","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/JCO.20.02613","volume":"38","author":"JR Lurain","year":"2020","unstructured":"Lurain JR, Schink JC. Immunotherapy versus chemotherapy for methotrexate-resistant low-risk gestational trophoblastic neoplasia. J Clin Oncol. 2020;38(36):4349\u201350.","journal-title":"J Clin Oncol"},{"key":"3482_CR71","unstructured":"ClinicalTrials.gov. Avelumab and methotrexate in low-risk gestational trophoblastic neoplasias as first line treatment (TROPHAMET). Identifier: NCT04396223. https:\/\/clinicaltrials.gov\/study\/NCT04396223. Accessed Oct 31, 2025."},{"issue":"Suppl 1","key":"3482_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2025.03.068","volume":"200","author":"B You","year":"2025","unstructured":"You B, Lotz J, Descargues P, et al. Avelumab plus methotrexate in low-risk gestational trophoblastic tumors in first-line setting: updated analysis of TROPHAMET trial on efficacy and subsequent pregnancies. Gynecol Oncol. 2025;200(Suppl 1):14.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3482_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41392-022-01213-6","volume":"8","author":"Y Ma","year":"2023","unstructured":"Ma Y, Cao J, Zhang Y, et al. Phase\u00a0I study of camrelizumab in patients with advanced solid tumors. Signal Transduct Target Ther. 2023;8(1):47.","journal-title":"Signal Transduct Target Ther"},{"key":"3482_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937307","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Huang H, Zhang T, et al. Apatinib: a novel antiangiogenic drug in monotherapy or combination immunotherapy for digestive system malignancies. Front Immunol. 2022;13:937307.","journal-title":"Front Immunol"},{"issue":"11","key":"3482_CR75","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S1470-2045(21)00524-6","volume":"22","author":"KM Elias","year":"2021","unstructured":"Elias KM, Braga A, Horowitz NS, Berkowitz RS. A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. Lancet Oncol. 2021;22(11):1490\u20131.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3482_CR76","volume":"7","author":"W Liu","year":"2024","unstructured":"Liu W, Zhu Y, Wang Y, et al. Role of immune checkpoint inhibitors combined with chemotherapy in recurrent drug-resistant gestational trophoblastic neoplasia: four case reports and literature review. Cancer Rep (Hoboken). 2024;7(3):e2016.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"8","key":"3482_CR77","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/biomedicines10081822","volume":"10","author":"MC Merlano","year":"2022","unstructured":"Merlano MC, Denaro N, Galizia D, et al. How chemotherapy affects the tumor immune microenvironment: a narrative review. Biomedicines. 2022;10(8):1822.","journal-title":"Biomedicines"},{"issue":"8","key":"3482_CR78","doi-asserted-by":"publisher","DOI":"10.4161\/onci.25961","volume":"2","author":"C Devaud","year":"2013","unstructured":"Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013;2(8):e25961.","journal-title":"Oncoimmunology"},{"key":"3482_CR79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","volume":"1224","author":"M Dysthe","year":"2020","unstructured":"Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:117\u201340.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"3482_CR80","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/aogs.14404","volume":"101","author":"YM Hoeijmakers","year":"2022","unstructured":"Hoeijmakers YM, Simons M, Bulten J, et al. PD-L1 in gestational trophoblastic disease: an antibody evaluation. Acta Obstet Gynecol Scand. 2022;101(9):1007\u201316.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"3482_CR81","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.4143\/crt.2021.1133","volume":"54","author":"J Hyung","year":"2022","unstructured":"Hyung J, Cho EJ, Kim J, et al. Histopathologic and molecular biomarkers of PD-1\/PD-L1 inhibitor treatment response among patients with microsatellite instability\u2013high colon cancer. Cancer Res Treat. 2022;54(4):1175\u201390.","journal-title":"Cancer Res Treat"},{"key":"3482_CR82","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","volume":"9","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment\u2014a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474.","journal-title":"Front Immunol"},{"issue":"1","key":"3482_CR83","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12884-019-2218-6","volume":"19","author":"M Meggyes","year":"2019","unstructured":"Meggyes M, Miko E, Szigeti B, Farkas N, Szereday L. The importance of the PD-1\/PD-L1 pathway at the maternal-fetal interface. BMC Pregnancy Childbirth. 2019;19(1):74.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"43","key":"3482_CR84","doi-asserted-by":"publisher","first-page":"13312","DOI":"10.1073\/pnas.1517724112","volume":"112","author":"T Tilburgs","year":"2015","unstructured":"Tilburgs T, Evans JH, Crespo \u00c2C, Strominger JL. The HLA-G cycle provides for both NK tolerance and immunity at the maternal-fetal interface. Proc Natl Acad Sci USA. 2015;112(43):13312\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"3482_CR85","first-page":"492","volume":"42","author":"JR Brahmer","year":"2024","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2024;42(6):492\u2013523.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3482_CR86","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1664\u201378.","journal-title":"Ann Oncol"},{"issue":"12","key":"3482_CR87","first-page":"1846","volume":"43","author":"K Oktay","year":"2025","unstructured":"Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025;43(12):1846\u201369.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3482_CR88","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ygyno.2016.10.024","volume":"144","author":"NS Horowitz","year":"2017","unstructured":"Horowitz NS, Goldstein DP, Berkowitz RS. Placental site trophoblastic tumors and epithelioid trophoblastic tumors: biology, natural history, and treatment modalities. Gynecol Oncol. 2017;144(1):208\u201314.","journal-title":"Gynecol Oncol"},{"key":"3482_CR89","unstructured":"ClinicalTrials.gov. Phase\u00a0II trial for chemo-resistant gestational trophoblastic neoplasias with pembrolizumab (CR-GTP). Identifier NCT04303884. https:\/\/www.clinicaltrials.gov\/study\/NCT04303884. Accessed Nov 2, 2025."},{"key":"3482_CR90","unstructured":"ClinicalTrials.gov. Camrelizumab combined with apatinib for recurrent resistant gestational trophoblastic neoplasia. Identifier NCT04047017. https:\/\/clinicaltrials.gov\/study\/NCT04047017. Accessed Nov 2, 2025."},{"key":"3482_CR91","unstructured":"ClinicalTrials.gov. Camrelizumab plus apatinib in patients with high-risk gestational trophoblastic neoplasia. Identifier NCT05139095. https:\/\/clinicaltrials.gov\/study\/NCT05139095. Accessed Nov 2, 2025."},{"key":"3482_CR92","unstructured":"ClinicalTrials.gov. A feasibility window study of pembrolizumab prior to second evacuation for post-molar gestational trophoblastic neoplasia. Identifier NCT05635344. https:\/\/clinicaltrials.gov\/study\/NCT05635344. Accessed Oct 31, 2025."},{"key":"3482_CR93","unstructured":"ClinicalTrials.gov. Toripalimab plus actinomycin-D as first-line treatment for gestational trophoblastic neoplasia with FIGO score 7 (TA7). Identifier NCT06020755. https:\/\/clinicaltrials.gov\/study\/NCT06020755. Accessed Nov 2, 2025."},{"key":"3482_CR94","unstructured":"ClinicalTrials.gov. Toripalimab plus actinomycin-D as first-line treatment for gestational trophoblastic neoplasia (FIGO score 5\u20136). Identifier NCT06028672. https:\/\/clinicaltrials.gov\/study\/NCT06028672. Accessed Nov 2, 2025."},{"key":"3482_CR95","unstructured":"ClinicalTrials.gov. IMMUNORARE5: a National Platform of 5 Academic Phase\u00a0II trials to assess the safety and efficacy of domvanalimab + zimberelimab in advanced rare cancers. Identifier NCT06790706. https:\/\/clinicaltrials.gov\/study\/NCT06790706. Accessed Nov 2, 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03482-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:02:37Z","timestamp":1773824557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03482-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3482"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03482-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marcio Bezerra Barcellos, Ant\u00f4nio Braga, Raphael Alevato, Sully Turon, Gustavo Yano Callado, Solange Artimos, Sue Yazaki Sun, Jorge Rezende-Filho, Edward Araujo J\u00fanior, Ross S. Berkowitz, Neil S. Horowitz, and Roberta Granese declare that they have nothing to disclose. Andreia C. de Melo discloses receiving grants or contracts with her institution from Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Daiichi-Sankyo, GlaxoSmithKline, MSD, Novartis, Regeneron and Roche; honoraria from AbbVie, Adium Pharma, AstraZeneca, Bristol Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, MSD, Novartis and Pfizer; meeting attendance and\/or travel support from AbbVie, AstraZeneca, Daiichi-Sankyo and MSD; and participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Bristol Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, MSD. These relationships are unrelated to the present study. Dr. Roberta Granese is an Editorial Board member of\n                      Advances in Therapy\n                      . She was not involved in the selection of peer reviewers nor in any of the editorial decisions related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is a narrative review based exclusively on previously published studies and does not involve any new research with human participants or animals conducted by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}